Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications

Abstract

Aim-The first-episode psychosis (FEP) represents a critical period to prevent cardiovascular and metabolic morbidity decades later. Antipsychotic (AP)-induced weight gain is one modifiable factor in this period. The purpose of this study is to conduct a meta-analysis of AP-induced weight and body mass index (BMI) change in FEP.Methods-A comprehensive literature search identified 28 articles that reported data on APspecific weight or BMI change in FEP. We conducted a meta-analysis of short-and long-term mean weight and BMI differences between placebo and AP medications. We also performed subgroup and meta-regression analysis to examine weight, BMI outcomes and their relationship with location (Asian vs. Western), sponsorship and baseline weight and BMIs.Results-Compared to placebo, AP-caused mean weight gain was 3.22 kg and 1.4 points BMI in the short-term, and 5.30 kg and 1.86 points BMI in the long term. Clinically significant weight gain risk increased about twofold with AP use. Weight gain was associated with duration of AP use. AP medications were associated with more weight gain in Western samples as opposed to Asian samples. Most AP medications were associated with significant body weight gain and BMI increase in FEP patients, except for ziprasidone. Olanzapine and clozapine caused the highest weight gain compared to placebo.Conclusion-Except for ziprasidone, most AP medications were associated with body weight gain and BMI increase in FEP patients. Early and continuing effects of various AP medications on weight gain and BMI increase should be taken into consideration by clinicians.

Weight gain during incarceration: systematic review and meta‐analysis

“…Medications used to treat some of these mental health issues (e.g. antipsychotics and antidepressants) are also known to affect weight . In the study by Drach et al .…”

Keeping the body in mind: A qualitative analysis of the experiences of people experiencing first‐episode psychosis participating in a lifestyle intervention programme

“…The primary reason for this premature mortality is cardiovascular disease, which is precipitated by underlying risk factors such as of diabetes, hyperlipidaemia, obesity, and hypertension. Weight gain and metabolic changes have been consistently associated with use of atypical antipsychotics that are frequently prescribed for people with a SMI (Almandil et al ; Alvarez‐Jimenez et al ; Tek et al ). These circumstances not only result in a reduced life expectancy, but also negatively impact quality of life (Awad & Voruganti ).…”

Codesigned recommendations for increasing engagement in structured physical activity for people with serious mental health problems in Australia

“…The higher rates of comorbid health conditions and early mortality due to physical illness in people with mental health problems are well reported. Contributing factors to poorer health outcomes in people experiencing mental health problems are complex and involve a convergence of influences including socioeconomic; medication effects; lack of social supports; poor engagement with, and/or access to, healthcare services; poor physical health monitoring, and lifestyle factors, including higher rates of smoking, poor diet, and lower levels of physical activity (McNamee, Mead, MacGillivray, & Lawrie, ; Tek et al, ). Modification of lifestyle factors such as increasing physical activity and improving diet has been associated with reduced risk for poor health outcomes and engagement in physical activity has been increasingly linked with improved mental health outcomes (Rosenbaum, Tiedemann, Sherrington, Curtis, & Ward, ).…”